BioSpace News Archive

EnteroBiotix Limited, a clinical stage company with the premier platform for full-spectrum microbiome therapeutics, announced the appointment to its Board of Elmar Schnee as Executive Chairman.

COMPASS Pathways plc announced that positive data from an open-label phase 2 clinical trial of investigational COMP360 psilocybin in addition to daily selective serotonin reuptake inhibitors in treatment-resistant depression has been published online in the peer reviewed Nature journal, Neuropsychopharmacology.

GeneQuantum and InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting drug resistance for hard-to-treat solid tumors, signed a collaboration agreement.

Westlake Village BioPartners announced the launch of its third fund of $450 million to incubate and grow early stage next-generation biotechnology companies in the Los Angeles region and beyond.

Eleven Therapeutics, a biotechnology company developing next-generation RNA therapeutics through the mastery of combinatorial chemistry and artificial intelligence, announced a research collaboration with the global healthcare company Novo Nordisk.

HF1K16 is a new immuno-oncology drug targeting myeloid-derived suppressor cells (MDSC) to treat cancer

ProKidney Corp. announced the appointment of Bruce Culleton, MD, as Executive Vice President, Clinical Development and Commercialization.

Biora Therapeutics, Inc., the biotech company that is reimagining therapeutic delivery, announced that it will report financial results and provide a corporate update for the second quarter ended June 30, 2023.

LianBio announced data from the Phase 3 EXPLORER-CN trial of mavacamten in Chinese symptomatic obstructive hypertrophic cardiomyopathy patients were accepted for a late-breaking presentation at the European Society of Cardiology Congress 2023 taking place August 25-28, 2023 in Amsterdam, Netherlands.

Rhythm Pharmaceuticals, Inc. announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 1, 2023 to report its second quarter 2023 financial results and provide a corporate update.